As a disruptive technology leading the new round of scientific and technological revolution and industrial transformation, artificial intelligence has become a new focus of international competition and a powerful engine for economic development. In the field of healthcare and medicine, artificial intelligence has been applied to areas such as target discovery, drug design, and clinical trials, significantly enhancing research efficiency. However, pharmaceutical products are special commodities whose quality directly affects the life and health of patients. The application of artificial intelligence in drug research and development has certain limitations and raises ethical and legal issues. This study aims to explore the current application status of artificial intelligence in pharmaceutical research and development and its regulatory policies, analyze its potential and limitations in areas such as target identification, compound screening, and clinical trial optimization, and provide relevant recommendations for the development and regulation of artificial intelligence in the pharmaceutical field by comparing domestic and international regulatory strategies of artificial intelligence application, promoting the safe and efficient application of artificial intelligence in pharmaceutical research and development.

无